MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Celldex Therapeutics Total Assets 2011-2026 | CLDX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Celldex Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 792 M | 466 M | 353 M | 445 M | 236 M | 123 M | 156 M | 316 M | 383 M | 338 M | 248 M | 347 M | 126 M | 98 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 792 M | 98 M | 316 M |
Quarterly Total Assets Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 648 M | 692 M | 739 M | 792 M | 823 M | 846 M | 869 M | 466 M | 280 M | 299 M | 325 M | 353 M | 369 M | 403 M | 424 M | 445 M | 460 M | 205 M | 219 M | 236 M | 236 M | 236 M | 236 M | 123 M | 123 M | 123 M | 123 M | 156 M | 156 M | 156 M | 156 M | 316 M | 316 M | 316 M | 316 M | 383 M | 383 M | 383 M | 383 M | 338 M | 338 M | 338 M | 338 M | 248 M | 248 M | 248 M | 248 M | 347 M | 347 M | 347 M | 347 M | 126 M | 126 M | 126 M | 126 M | 98 M | 98 M | 98 M | 98 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 869 M | 98 M | 324 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
28 B | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
89.3 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 117.62 | 1.41 % | $ 27.2 B | Germany |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 11.66 | -8.95 % | $ 768 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
38.3 M | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
BioLineRx Ltd.
BLRX
|
38.9 M | $ 3.12 | 0.59 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Cellectis S.A.
CLLS
|
384 M | $ 4.13 | -6.56 % | $ 116 M | France |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 233.49 | -0.81 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 9.71 | -0.46 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
115 M | $ 2.04 | -2.39 % | $ 183 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
630 M | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
3.5 B | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 94.24 | 1.38 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |